The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa

Hessel H. Van Der Zee, Jurr Boer, Errol P. Prens, Gregor B.E. Jemec

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks. Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations. Method: A retrospective study in 34 patients. Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease. Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established.

OriginalsprogEngelsk
Sider (fra-til)143-147
Antal sider5
TidsskriftDermatology
Vol/bind219
Udgave nummer2
DOI
StatusUdgivet - 1 aug. 2009

Fingeraftryk

Udforsk hvilke forskningsemner 'The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa' indeholder.

Citationsformater